文献速递临床试验与 GCP医学人工智能与信息学

治疗性智能手机应用对年轻人自杀意念的影响:澳大利亚随机对照试验结果

The effect of a therapeutic smartphone application on suicidal ideation in young adults: Findings from a randomized controlled trial in Australia.
PubMed 文献 · PLoS Med · 2022-05-31

这项在澳大利亚开展的2臂平行双盲随机对照试验纳入455名18至25岁近期有自杀意念的年轻人,按2:2随机分配使用LifeBuoy或注意力匹配对照应用6周。LifeBuoy在干预后和3个月随访时对自杀意念严重程度的改善优于对照应用,但在抑郁、焦虑、痛苦和幸福感等次要结局上无优势。

要点

  • LifeBuoy在干预后(p<0.001,d=0.45)和3个月随访(p=0.007,d=0.34)对自杀意念严重程度的改善优于对照应用。
  • LifeBuoy在抑郁、焦虑、痛苦和幸福感等次要结局上从基线到干预后或3个月随访均无优势(p值范围0.069至0.896)。
  • 未报告严重不良事件(需要医疗护理的自杀未遂)。

核心结论

  • 与对照应用LifeBuoy-C相比,LifeBuoy与自杀意念严重程度的更优改善相关,但在次要心理健康结局上无优势。
  • 数字疗法可能需要有目的地设计以针对特定健康结局才能产生疗效。

研究设计与样本

  • 2臂平行、双盲、随机对照试验,在澳大利亚在线开展,采用定向社交媒体招募策略。
  • 455名18至25岁近期有自杀意念的年轻人按2:2比例随机分配,使用智能手机应用6周,2020年5月开始,最终随访于2020年10月。
  • LifeBuoy组228人,对照应用LifeBuoy-C组227人;LifeBuoy组110人未完成最终调查,对照组91人未完成最终调查;所有随机参与者均纳入意向性治疗分析。
  • 干预组使用基于辩证行为疗法(DBT)的自助智能手机应用LifeBuoy,旨在改善情绪调节和痛苦耐受;对照组使用外观类似LifeBuoy的LifeBuoy-C,提供一般(非治疗性)健康与生活方式信息。

主要发现

  • 自杀意念评分存在显著时间×条件交互效应,在干预后(p<0.001,d=0.45)和3个月随访(p=0.007,d=0.34)均有利于LifeBuoy。
  • 从基线到干预后或3个月随访,LifeBuoy在任何次要心理健康结局上均无优势干预效应(p值范围0.069至0.896)。
  • 未报告严重不良事件(需要医疗护理的自杀未遂)。

局限性

  • 缺乏支持该研究有足够把握度检测次要结局变化的样本量计算。
  • 3个月随访时脱落率高,可能导致疗效被高估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Suicidal ideation is a major risk for a suicide attempt in younger people, such that reducing severity of ideation is an important target for suicide prevention. Smartphone applications present a new opportunity for managing ideation in young adults; however, confirmatory evidence for efficacy from randomized trials is lacking. The objective of this study was to assess whether a therapeutic smartphone application ("LifeBuoy") was superior to an attention-matched control application at reducing the severity of suicidal ideation. METHODS AND FINDINGS: In this 2-arm parallel, double-blind, randomized controlled trial, 455 young adults from Australia experiencing recent suicidal ideation and aged 18 to 25 years were randomly assigned in a 2:2 ratio to use a smartphone application for 6 weeks in May 2020, with the final follow-up in October 2020. The primary outcome was change in suicidal ideation symptom severity scores from baseline (T0) to postintervention (T1) and 3-month postintervention follow-up (T2), measured using the Suicidal Ideation Attributes Scale (SIDAS). Secondary outcomes were symptom changes in depression (Patient Health Questionnaire-9, PHQ-9), generalized anxiety (Generalized Anxiety Disorder-7, GAD-7), distress (Distress Questionnaire-5, DQ5), and well-being (Short Warwick-Edinburgh Mental Well-Being Scale, SWEMWBS). This trial was conducted online, using a targeted social media recruitment strategy. The intervention groups were provided with a self-guided smartphone application based on dialectical behavior therapy (DBT; "LifeBuoy") to improve emotion regulation and distress tolerance. The control group were provided a smartphone application that looked like LifeBuoy ("LifeBuoy-C"), but delivered general (nontherapeutic) information on a range of health and lifestyle topics. Among 228 participants randomized to LifeBuoy, 110 did not complete the final survey; among 227 participants randomized to the control condition, 91 did not complete the final survey. All randomized participants were included in the intent-to-treat analysis for the primary and secondary outcomes. There was a significant time × condition effect for suicidal ideation scores in favor of LifeBuoy at T1 (p < 0.001, d = 0.45) and T2 (p = 0.007, d = 0.34). There were no superior intervention effects for LifeBuoy on any secondary mental health outcomes from baseline to T1 or T2 [p-values: 0.069 to 0.896]. No serious adverse events (suicide attempts requiring medical care) were reported. The main limitations of the study are the lack of sample size calculations supporting the study to be powered to detect changes in secondary outcomes and a high attrition rate at T2, which may lead efficacy to be overestimated. CONCLUSIONS: LifeBuoy was associated with superior improvements in suicidal ideation severity, but not secondary mental health outcomes, compared to the control application, LifeBuoy-C. Digital therapeutics may need to be purposefully designed to target a specific health outcome to have efficacy. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12619001671156.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Torok M, Han J, McGillivray L, et al. The effect of a therapeutic smartphone application on suicidal ideation in young adults: Findings from a randomized controlled trial in Australia. PLoS Med. 2022. PMID: 35639672. doi:10.1371/journal.pmed.1003978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。